X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NOVARTIS - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NOVARTIS FRESENIUS KABI ONCO./
NOVARTIS
 
P/E (TTM) x 22.1 391.0 5.7% View Chart
P/BV x 3.1 19.3 16.2% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 FRESENIUS KABI ONCO.   NOVARTIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NOVARTIS
Mar-16
FRESENIUS KABI ONCO./
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs176982 17.9%   
Low Rs79556 14.1%   
Sales per share (Unadj.) Rs37.7252.9 14.9%  
Earnings per share (Unadj.) Rs5.162.1 8.2%  
Cash flow per share (Unadj.) Rs6.763.3 10.6%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs42.5363.6 11.7%  
Shares outstanding (eoy) m158.2331.96 495.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.0 111.0%   
Avg P/E ratio x25.012.4 201.9%  
P/CF ratio (eoy) x18.912.2 155.8%  
Price / Book Value ratio x3.02.1 141.4%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m20,13524,580 81.9%   
No. of employees `0001.20.8 153.2%   
Total wages/salary Rs m7031,801 39.0%   
Avg. sales/employee Rs Th5,176.210,748.9 48.2%   
Avg. wages/employee Rs Th610.42,395.2 25.5%   
Avg. net profit/employee Rs Th699.62,641.1 26.5%   
INCOME DATA
Net Sales Rs m5,9638,083 73.8%  
Other income Rs m18829 2.2%   
Total revenues Rs m5,9818,913 67.1%   
Gross profit Rs m1,430234 610.6%  
Depreciation Rs m25837 702.7%   
Interest Rs m-262 -1,444.4%   
Profit before tax Rs m1,2161,025 118.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m-681,696 -4.0%   
Tax Rs m342752 45.5%   
Profit after tax Rs m8061,986 40.6%  
Gross profit margin %24.02.9 827.7%  
Effective tax rate %28.173.4 38.4%   
Net profit margin %13.524.6 55.0%  
BALANCE SHEET DATA
Current assets Rs m5,10212,678 40.2%   
Current liabilities Rs m2,3852,433 98.0%   
Net working cap to sales %45.6126.7 35.9%  
Current ratio x2.15.2 41.0%  
Inventory Days Days15033 458.9%  
Debtors Days Days11322 503.8%  
Net fixed assets Rs m5,14869 7,439.5%   
Share capital Rs m158160 99.0%   
"Free" reserves Rs m6,55611,460 57.2%   
Net worth Rs m6,73211,621 57.9%   
Long term debt Rs m9520-   
Total assets Rs m10,38814,400 72.1%  
Interest coverage x-45.8570.5 -8.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.6 102.3%   
Return on assets %7.513.8 54.4%  
Return on equity %12.017.1 70.0%  
Return on capital %14.623.6 61.9%  
Exports to sales %74.50.7 9,999.2%   
Imports to sales %24.818.6 133.3%   
Exports (fob) Rs m4,44160 7,376.4%   
Imports (cif) Rs m1,4771,503 98.3%   
Fx inflow Rs m5,298186 2,843.6%   
Fx outflow Rs m1,7721,821 97.3%   
Net fx Rs m3,525-1,635 -215.7%   
CASH FLOW
From Operations Rs m1,2742,531 50.3%  
From Investments Rs m-1,204-8,270 14.6%  
From Financial Activity Rs m-196-386 50.8%  
Net Cashflow Rs m-126-6,125 2.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 9.6 1.6 600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   42,599 41,647 102.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Rising Stock Markets, Reduction in Government's Additional Borrowing, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a strong note yesterday. At the closing bell yesterday, the BSE Sensex crossed its 35,000 mark for the first time and stood higher by 311 points (up 0.9%).

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS